All Updates

All Updates

icon
Filter
Partnerships
Logix Biosciences and Mayo Clinic partner to develop targeted therapies for allergy relief
Precision Medicine
Jun 12, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Yesterday
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Yesterday
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Yesterday
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Yesterday
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Yesterday
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Yesterday
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
Precision Medicine

Precision Medicine

Jun 12, 2024

Logix Biosciences and Mayo Clinic partner to develop targeted therapies for allergy relief

Partnerships

  • Logix Biosciences has partnered with Mayo Clinic to share knowledge to produce precision therapeutics for unmet needs in its focus areas of allergy relief, infectious disease protection, and antimicrobial resistance.

  • The partnership will leverage Logix Biosciences' expertise in drug development and Mayo Clinic's research capabilities to develop Logix's pipeline, including an active ingredient derived from medical-grade manuka honey. The aim is to advance the clinical development of the ingredient into the lead drug candidate. Studies are planned to commence immediately with preclinical work. Subject to necessary funding, clinical trials are expected to be initiated later this year. 

  • Logix Biosciences specializes in nasal immune modulation, focusing on developing novel therapeutics for underserved medical needs such as allergy relief, mutating infectious diseases, and bacterial resistance. The company’s non-drug OTC nasal spray is designed to clean allergens and particulate matter from the nasal cavities.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.